A dabrafenib and trametinib combination (hereafter D/T combination) significantly improved response rates (76% vs. 54%), prolonged progression-free survival (PFS; 9.4 versus 5.8 months), and reduced skin toxicities compared with dabrafenib monotherapy in BRAF melanoma patients [4]. This evidence concerns the gene BRAF and melanoma.